Impact Capital Partners LLC Sells 1,382 Shares of Pfizer Inc. $PFE

Impact Capital Partners LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 10.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 12,304 shares of the biopharmaceutical company’s stock after selling 1,382 shares during the period. Impact Capital Partners LLC’s holdings in Pfizer were worth $298,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Forza Wealth Management LLC raised its holdings in Pfizer by 16.7% during the second quarter. Forza Wealth Management LLC now owns 15,290 shares of the biopharmaceutical company’s stock worth $371,000 after acquiring an additional 2,188 shares in the last quarter. PFG Investments LLC raised its stake in Pfizer by 5.9% in the second quarter. PFG Investments LLC now owns 250,474 shares of the biopharmaceutical company’s stock valued at $6,071,000 after buying an additional 14,016 shares during the period. Columbia Asset Management raised its stake in Pfizer by 9.4% in the second quarter. Columbia Asset Management now owns 186,168 shares of the biopharmaceutical company’s stock valued at $4,513,000 after buying an additional 15,957 shares during the period. Wetzel Investment Advisors Inc. raised its stake in Pfizer by 126.4% in the second quarter. Wetzel Investment Advisors Inc. now owns 18,757 shares of the biopharmaceutical company’s stock valued at $455,000 after buying an additional 10,472 shares during the period. Finally, Westhampton Capital LLC raised its stake in Pfizer by 9.9% in the second quarter. Westhampton Capital LLC now owns 46,778 shares of the biopharmaceutical company’s stock valued at $1,134,000 after buying an additional 4,200 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research analyst reports. Bank of America upped their price objective on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday. UBS Group restated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday. Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Finally, Morgan Stanley upped their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $28.29.

Pfizer Stock Up 6.8%

PFE opened at $27.21 on Thursday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market capitalization of $154.68 billion, a P/E ratio of 14.47, a P/E/G ratio of 0.82 and a beta of 0.55. The stock has a fifty day moving average of $24.59 and a 200-day moving average of $24.14.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.